Apheresis (for Louisiana Only)
Policy governs medical necessity and coverage of therapeutic apheresis procedures (e.g., plasma exchange, photopheresis, LDL apheresis) for Louisiana Medicaid members and providers in Louisiana.
Replaced language indicating therapeutic apheresis was unproven and not medically necessary for treating the listed conditions with language stating it is unproven and not medically necessary for treating any other conditions/diagnoses not listed as proven and medically necessary.
Added medical records documentation language specifying that benefit coverage is determined by federal, state, or contractual requirements, and that medical records may be required to assess whether clinical criteria for coverage are met.
Policy retired for Louisiana plan membership effective April 1, 2026.
Updated Clinical Evidence, FDA, and References sections to reflect the most current information.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.